FLT3 signaling and the development of inhibitors that target FLT3 kinase activity
- PMID: 22471708
- DOI: 10.1615/critrevoncog.v17.i2.50
FLT3 signaling and the development of inhibitors that target FLT3 kinase activity
Abstract
The FMS-like receptor tyrosine kinase-3 (FLT3) plays a key role in hematopoietic development and is frequently mutated in patients with acute myeloid leukemia (AML). These mutations render FLT3 constitutively active, and patients harboring these mutations have a poor prognosis. Targeting the kinase activity of FLT3 with inhibitory compounds is therefore an attractive therapeutic option. Over the last few years, numerous FLT3 inhibitors have undergone clinical trials. Although some have been disappointing, some newer agents have shown promise. This review provides an overview of FLT3 signaling, recent progress with next-generation inhibitors, and unexpected hurdles encountered when combining FLT3 inhibitors with chemotherapy.
Similar articles
-
The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.Hematol Oncol Clin North Am. 2017 Aug;31(4):663-680. doi: 10.1016/j.hoc.2017.03.002. Epub 2017 May 17. Hematol Oncol Clin North Am. 2017. PMID: 28673394 Review.
-
The Future of Targeting FLT3 Activation in AML.Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2. Curr Hematol Malig Rep. 2017. PMID: 28421420 Review.
-
FLT3 inhibitors in acute myeloid leukemia: Current and future.J Oncol Pharm Pract. 2019 Jan;25(1):163-171. doi: 10.1177/1078155218802620. Epub 2018 Sep 30. J Oncol Pharm Pract. 2019. PMID: 30270754 Review.
-
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.J Hematol Oncol. 2020 Nov 19;13(1):155. doi: 10.1186/s13045-020-00992-1. J Hematol Oncol. 2020. PMID: 33213500 Free PMC article. Review.
-
FLT3 Inhibitors for Treating Acute Myeloid Leukemia.Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):543-549. doi: 10.1016/j.clml.2016.06.002. Epub 2016 Jun 25. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27450971 Review.
Cited by
-
Flk2/Flt3 promotes both myeloid and lymphoid development by expanding non-self-renewing multipotent hematopoietic progenitor cells.Exp Hematol. 2014 Mar;42(3):218-229.e4. doi: 10.1016/j.exphem.2013.11.013. Epub 2013 Dec 11. Exp Hematol. 2014. PMID: 24333663 Free PMC article.
-
Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.Nat Chem Biol. 2013 Dec;9(12):840-848. doi: 10.1038/nchembio.1367. Epub 2013 Oct 27. Nat Chem Biol. 2013. PMID: 24161946 Free PMC article.
-
Molecular therapeutic approaches for pediatric acute myeloid leukemia.Front Oncol. 2014 Mar 18;4:55. doi: 10.3389/fonc.2014.00055. eCollection 2014. Front Oncol. 2014. PMID: 24672775 Free PMC article. Review.
-
Update on optimal management of acute myeloid leukemia.Clin Med Insights Oncol. 2013 Aug 12;7:181-97. doi: 10.4137/CMO.S8528. eCollection 2013. Clin Med Insights Oncol. 2013. PMID: 23997579 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous